Health AI Central
Share:
Peer-Reviewed Publication
Front Pharmacol2026;171771657.January 1, 2026Journal Article

Latrepirdine (Dimebon), a potent 5-HT7 receptor antagonist, modulates stress-mediated behaviors in rodents.

Dinesh K Dhull1, Subhendu Seth1, Frank D Yocca2, Michael De Vivo2
1E. Z. BioXcel Solutions Pvt. Ltd., Gurugram, Haryana, India.
2BioXcel Therapeutics Inc., New Haven, CT, United States.
PubMed PMC DOI PDF

Abstract

OBJECTIVES: First, determine the likely molecular target of latrepirdine. Second, using stress-mediated rodent behavioral models, determine which clinical neuropsychiatric symptoms are possibly improved by latrepirdine. Third, establish whether latrepirdine possesses properties suitable for chronic treatment of neuropsychiatric symptoms related to stress. METHODS: Characterization of the potency…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.